RGLS - Regulus Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue72721,19420,759
Cost of Revenue33,94454,59164,30556,387
Gross Profit-33,872-54,519-63,111-35,628
Operating Expenses
Research Development----
Selling General and Administrative12,87513,33218,39119,130
Non Recurring----
Others----
Total Operating Expenses46,81967,92382,69675,517
Operating Income or Loss-46,747-67,851-81,502-54,758
Income from Continuing Operations
Total Other Income/Expenses Net-1,900-4,251-338-1,008
Earnings Before Interest and Taxes-46,747-67,851-81,502-54,758
Interest Expense-2,343-2,723-1,182-52
Income Before Tax-48,647-72,102-81,840-55,766
Income Tax Expense62-197-4-18
Minority Interest----
Net Income From Continuing Ops-48,709-71,905-81,836-55,748
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-48,709-71,905-81,836-55,748
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-48,709-71,905-81,836-55,748